

1 **Social and structural determinants of injection drug use-associated**  
2 **bacterial and fungal infections: a qualitative systematic review and**  
3 **thematic synthesis**

4

5 Running title: Determinants of injecting-related infections

6

7

8 Thomas D. Brothers<sup>1,2</sup>, Matthew Bonn<sup>3</sup>, Dan Lewer<sup>1</sup>, Emilie Comeau<sup>4</sup>, Inhwa Kim<sup>4</sup>, Duncan Webster<sup>2,5</sup>,  
9 Andrew Hayward<sup>1</sup>, Magdalena Harris<sup>6</sup>

10

11 <sup>1</sup>UCL Collaborative Centre for Inclusion Health, Institute of Epidemiology and Health Care, University  
12 College London, London, UK

13 <sup>2</sup>Department of Medicine, Faculty of Medicine, Dalhousie University, Halifax, Canada

14 <sup>3</sup>Canadian Association of People who Use Drugs (CAPUD), Dartmouth, Canada

15 <sup>4</sup>Faculty of Medicine, Dalhousie University, Halifax, Canada

16 <sup>5</sup>Division of Infectious Diseases, Saint John Regional Hospital, Saint John, Canada

17 <sup>6</sup>Department of Public Health, Environments and Society, London School of Hygiene & Tropical  
18 Medicine, London, UK

19

20

21 Address correspondence to: thomas.brothers.20@ucl.ac.uk; thomas.brothers@dal.ca (TDB)

22

23 **ABSTRACT**

24 **Background:** Injection drug use-associated bacterial and fungal infections are increasingly common, and  
25 social contexts shape individuals' injecting practices and treatment experiences. We sought to  
26 synthesize qualitative studies of social-structural factors influencing incidence and treatment of  
27 injecting-related infections.

28 **Methods:** We searched PubMed, EMBASE, Scopus, CINAHL, and PsycINFO from January 1, 2000, to  
29 February 18, 2021. Informed by Rhodes' "risk environment" framework, we performed thematic  
30 synthesis in three stages: (1) line-by-line coding; (2) organizing codes into descriptive themes, reflecting  
31 interpretations of study authors; (3) consolidating descriptive themes into conceptual categories to  
32 identify higher-order analytic themes.

33 **Results:** We screened 4,841 abstracts and included 26 qualitative studies on experiences of injecting-  
34 related bacterial and fungal infections. We identified six descriptive themes organized into two analytic  
35 themes. The first analytic theme, *social production of risk*, considered macro-environmental influences.  
36 Four descriptive themes highlighted pathways through which this occurs: (1) *unregulated drug supply*,  
37 leading to poor drug quality and solubility; (2) *unsafe spaces*, influenced by policing practices and  
38 insecure housing; (3) *health care policies and practices*, leading to negative experiences that discourage  
39 access to care; and (4) *harm reduction programs*, including structural barriers to effective service  
40 provision. The second analytic theme, *practices of care among people who inject drugs*, addresses  
41 protective strategies that people who inject drugs employ within infection risk environments. Associated  
42 descriptive themes were: (5) *mutual care*, including assisted-injecting and sharing sterile equipment; and  
43 (6) *self-care*, including vein health and self-treatment. Within constraining risk environments, some  
44 protective strategies for bacterial infections precipitated other health risks (e.g., HIV transmission).

45 **Conclusions:** Injecting-related bacterial and fungal infections are shaped by modifiable social-structural  
46 factors, including unregulated drug quality, criminalization, insufficient housing, limited harm reduction

- 47 services, and harmful health care practices. Enabling environment interventions that address these
- 48 factors could further empower people who inject drugs to protect themselves and their community.

## 49 INTRODUCTION

50 Injection drug use-associated bacterial and fungal infections (e.g. skin and soft-tissue infections,  
51 endocarditis, epidural abscess) cause significant morbidity and mortality among people who inject drugs  
52 (PWID).<sup>1-6</sup> The incidence of hospitalizations for severe injecting-related infections is increasing in  
53 Australia,<sup>7</sup> Canada,<sup>2,8</sup> the United Kingdom (UK),<sup>9</sup> and the United States of America (USA).<sup>10-14</sup>

54  
55 Efforts to prevent injecting-related bacterial and fungal infections have focused on individual-level  
56 behavioural interventions,<sup>15,16</sup> including education on hand-washing before drug preparation,<sup>17</sup> skin-  
57 cleaning before injecting,<sup>18</sup> and avoiding subcutaneous/intramuscular injecting.<sup>19</sup> While individual-level  
58 interventions may be helpful for PWID who can adopt these practices, evaluations of these interventions  
59 have shown mixed results<sup>20-22</sup> and the incidence of injecting-related infections continues to rise.

60  
61 Risk for injecting-related bacterial and fungal infections likely reflects contributions of multiple factors  
62 external to PWID that enable and/or constrain their behaviour and influence health outcomes.<sup>23-26</sup>  
63 Identifying, measuring, and ameliorating such social-structural factors has informed clinical and public  
64 health responses to other drug-related harms, including HIV,<sup>27-29</sup> hepatitis C virus (HCV),<sup>30</sup> and  
65 overdose.<sup>31,32</sup> Understanding the influence of social context on health can broaden awareness of the  
66 causes of illness<sup>33</sup> and inform more appropriate prevention and treatment interventions.<sup>29,34,35</sup>

67

## 68 Objectives

69 To understand social-structural determinants of injecting-related bacterial and fungal infections and to  
70 identify opportunities for potential intervention, we aimed to: (1) systematically review qualitative  
71 studies on experiences of injecting-related infections, and (2) synthesize analyses of social-structural

72 factors influencing risk for injecting-related infections, their treatment, and subsequent health  
73 outcomes.

74

## 75 **METHODS**

76 Before conducting the search, we published our protocol<sup>1</sup> and registered with PROSPERO  
77 (CRD42021231411). We modified our original protocol after our search and full-text review. Our  
78 protocol specified a “mixed studies review” of quantitative, qualitative, and mixed-methods studies.<sup>38,39</sup>  
79 As we identified more and richer qualitative sources than anticipated, we decided to consider qualitative  
80 and quantitative data separately. Here, we report the qualitative systematic review and thematic  
81 synthesis. Quantitative results will be reported separately. This manuscript follows PRISMA guidelines<sup>36</sup>  
82 and the ENTREQ statement<sup>37</sup> on qualitative systematic reviews.

83

### 84 **Conceptual model and framework**

85 The “risk environment”, as developed by Rhodes and others,<sup>27,29,40,41</sup> is a socio-ecological model  
86 describing how macro-environmental (e.g., criminalization; racism) and micro-environmental (e.g., local  
87 availability of needle and syringe programs) factors interplay to influence health practices and  
88 outcomes.<sup>42</sup> The risk environment model encourages thinking about how people interact with and  
89 modify constraining environments (e.g., drug users’ unions organizing to repeal laws banning supervised  
90 consumption sites).<sup>43</sup> Collins and colleagues recently extended the risk environment to incorporate  
91 intersectionality, considering how social-structural factors affect PWID differently depending on other  
92 social identities and their locations within power hierarchies, including race and gender.<sup>42</sup>

93

94 Injecting-related bacterial and fungal infections occur through introducing bacteria or fungi into sterile  
95 tissues (often from commensal organisms living on the skin) and are precipitated by particulate matter

96 that damages blood vessels, lymphatics, and heart valves.<sup>35,44</sup> To conceptualise how the risk  
97 environment affects injecting-related infections at different times, we developed a framework (see  
98 Figure 1) illustrating a pathway from (a) drug acquisition (e.g. solubility of drugs); (b) drug preparation  
99 (e.g. using sterile water to dissolve drugs); (c) drug injection (e.g. accessing veins to avoid intramuscular  
100 injecting); (d) development of and care for superficial infections (e.g. self-treatment; primary care); (e)  
101 development of and care for severe infections (e.g. hospitalization); and (f) outcomes after infections  
102 (e.g. access to follow-up care).<sup>1</sup> Not all PWID would progress through all stages; some PWID do not  
103 develop infections and many who develop infections never access treatment.

104

#### 105 **Eligibility criteria**

106 A full description is in our published protocol.<sup>1</sup> Briefly, we included articles in peer-reviewed journals  
107 reporting qualitative studies. We followed the Population, Exposures, Outcomes approach to eligibility  
108 criteria.<sup>45</sup> The population was PWID (i.e., people injecting any psychoactive substance; excluding people  
109 only injecting performance-enhancing or gender-affirming hormones). Exposures were any social or  
110 environmental factors that may affect risk of infections, such as housing, service availability, or policing  
111 practices. Outcomes included incidence, treatment, or outcomes of injecting-related bacterial and  
112 fungal infections. Eligible studies were published in English or French between January 1, 2000, and  
113 February 18, 2021 (to capture contemporary research more likely to inform policy and clinical practice).

114

#### 115 **Information sources and search strategy**

116 We searched PubMed, EMBASE, Scopus, CINAHL, and PsycINFO databases. We developed the search  
117 strategy in consultation with a librarian (see Supplementary Table S1 for full search strategy). We  
118 supplemented searches with backward and forward citation chaining and with other studies known to

119 the review team (which includes people with lived/past and living/current experience of injection drug  
120 use, researchers, and clinicians caring for PWID).

121

## 122 **Data management and reference selection**

123 We uploaded titles/abstracts into Covidence software, where they were automatically de-duplicated.

124 Two reviewers (TDB and either MB, DL, EC, or IK) independently screened titles/abstracts, resolving

125 discrepancies through consensus. We obtained full-text reports for sources that passed screening, and

126 one reviewer (TDB) assessed full-text reports.

127

## 128 **Quality assessment**

129 We used the Mixed Methods Appraisal Tool (MMAT), which is a validated and commonly-used appraisal

130 tool for mixed studies reviews.<sup>46,46,47</sup> TDB and EC independently appraised each study, resolving

131 discrepancies through discussion. For data synthesis, we included studies meeting both MMAT

132 screening questions: “Are there clear research questions?” and “Do the collected data allow to address

133 the research questions?”

134

## 135 **Data synthesis**

136 Following Thomas and Harden,<sup>48-51</sup> thematic synthesis comprises three stages: (1) line-by-line open

137 coding; (2) organizing codes into descriptive themes reflecting content of studies and study authors’

138 interpretations; (3) translating descriptive themes and associated codes across studies to generate

139 analytic themes. Coding and generation of descriptive themes focuses on study authors’ analysis and

140 interpretation because reviewers do not have full knowledge of the original study data.<sup>48,49</sup>

141

142 First, TDB (physician and PhD student with qualitative methods training) familiarized himself with the  
143 included studies. Next, MB (researcher with lived/living experience of injecting-related infections and a  
144 drug policy activist) and TDB independently performed line-by-line coding on the same three  
145 purposefully selected, data rich sources.<sup>52-54</sup> They compared and contrasted codes and revised them in  
146 an iterative, deductive-inductive process, informed by the risk environment model.

147  
148 The whole review team met to provide feedback on these candidate codes: DL (public health specialist),  
149 EC and IK (medical students), DW (infectious diseases and addiction medicine physician), AK (infectious  
150 disease epidemiologist), and MH (health sociologist with lived experience of injection drug use). TDB  
151 coded the remaining papers over several rounds, including adding and revising new candidate codes  
152 after discussing with the team at meetings and through collaborative online writing.

153  
154 TDB developed descriptive themes by comparing and contrasting codes across studies, seeking to  
155 organize codes into related social-structural categories and proposed them to the team for feedback.  
156 TDB then consolidated descriptive themes into conceptual categories to generate analytic themes that  
157 were finalized over several iterations and team meetings.

158

## 159 **RESULTS**

160 Following de-duplication, we screened 4,841 titles/abstracts and evaluated 631 full-text reports. After  
161 considering 16 additional reports identified outside the search, we identified 151 eligible studies  
162 (quantitative, qualitative, and mixed-methods) for our “mixed studies” review. Here, we report on the  
163 26 studies with qualitative data and analysis (19 qualitative-only and seven mixed-methods). See Figure  
164 2 for PRISMA diagram. All 26 qualitative studies met our quality criteria for inclusion (see Supplementary  
165 Table S2 for full MMAT results).



166

## 167 **Study characteristics**

168 See Table 1 for summaries of individual studies. The majority (n=20 studies) were conducted in North  
169 America. Qualitative data came from individual interviews (n=23), observation/ethnography (n=4), and  
170 focus groups (n=2). Studies included experiences of injecting-related skin and soft-tissue infections  
171 (n=22), endocarditis (n=7), bacteremia (n=3), and osteomyelitis (n=2). All 26 studies included bacterial  
172 infections, and only one study<sup>55</sup> included fungal infections (candidemia and fungal ophthalmitis).

173

## 174 **Thematic synthesis**

### 175 *Summary*

176 We identified six descriptive themes organized into two analytic themes (see Figure 3).

177

178 The first analytic theme, *social production of risk*, considers how macro-environmental factors, including  
179 criminalization, poverty, structural stigma, mandated abstinence, and racism, shape risks for injecting-  
180 related infections. Four associated descriptive themes highlighted pathways through which this occurs:  
181 (1) *unregulated drug supply*, leading to poor drug quality and solubility; (2) *unsafe spaces*, influence by  
182 insecure housing and policing practices, and ameliorated by supervised consumption sites; (3) *health*  
183 *care policies and practices*, leading to experiences of discrimination and undertreated pain and  
184 withdrawal, which worsened infectious complications by alienating PWID and discouraging access to  
185 care; and (4) *harm reduction programs*, including structural barriers to effective service delivery.

186

187 The second analytic theme, *practices of care among people who use drugs*, addresses PWID expertise  
188 and agency in attempts to prevent and care for bacterial infections within constraining risk  
189 environments. Two associated descriptive themes categorized these practices as (5) *mutual care*,

190 including sharing sterile injecting equipment, assisting others with injecting into veins (rather than  
191 intramuscularly), and treating abscesses outside of medical settings; and (6) *self-care*, including  
192 promoting vein health and sourcing safer alternatives when sterile injecting equipment was unavailable.  
193 Within constraining risk environments, some of these mutual- and self-care protective strategies for  
194 bacterial infections precipitated other health risks, including HIV transmission or arterial injury.

195

196 Descriptive themes are detailed below, supplemented by quotations from study authors and  
197 participants (indicated in italics).

198

### 199 *Unregulated drug supply*

200 In five studies,<sup>52,54-57</sup> authors presented perspectives from PWID who attributed infections to the quality  
201 of unregulated drugs, including adulterants,<sup>52,54,55,57</sup> poor solubility,<sup>52,54-57</sup> and bacterial contamination,<sup>54</sup>  
202 especially through precipitating skin abscesses and vein sclerosis. Phillips and colleagues<sup>54</sup> reported that  
203 PWID in Denver (USA) commonly linked their bacterial infections to poor drug quality:

204

205 *"I think it's the dope because... I'll use a clean needle every time, and it still, it just depends on*  
206 *what they cut it with. You know, sometimes when you're cooking it, it's an okay color, and then*  
207 *the next time you're doing it you've got all this shit floating up, and it's all burnt around the*  
208 *sides."* (USA)<sup>54</sup>

209

210 In two studies,<sup>55,57</sup> authors analysed drivers of variation in the unregulated drug supply and associated  
211 infection risks. Mars and coauthors<sup>57</sup> identified that PWID in Philadelphia (USA) could purchase only tar  
212 heroin (which is less soluble than powder heroin, and is associated with greater bacterial infection risk)  
213 due to regional demarcation of supply networks. Harris and colleagues<sup>55</sup> highlighted London (England)

214 PWID accounts of changing drug quality over time which has impacted widespread overuse of citric acid,  
215 which is used to dissolve poorly soluble cutting agents or adulterants such as paracetamol and quinine.

216

217 *Unsafe spaces*

218 In eight studies,<sup>53,54,56,58-62</sup> investigators attributed increased bacterial infection risk to suboptimal drug  
219 preparation and injecting techniques created by unsafe spaces, including when PWID lacked housing  
220 and when trying to avoid being seen by police when using outdoors.

221

222 In six of these studies,<sup>53,56,58,60,61,63</sup> authors explored influences of being deprived of housing on infection  
223 risk. Lack of housing made it harder to prepare and inject drugs safely, including where there were no  
224 hygienic surfaces to prepare drugs,<sup>53,56,61</sup> inadequate lighting to find veins (leading to “missed hits” and  
225 inadvertent subcutaneous injection),<sup>53</sup> and no clean, running water to wash hands/skin or to dissolve  
226 drugs (leading PWID to use unhygienic water alternatives)<sup>56,58,60,61</sup>:

227

228 *“...there was no water actually and I had to use a bit of saliva. ...It worked, I still got my hit, but I*  
229 *also got the worst infection of my life, I nearly died ...Yeah, I was in hospital for nearly 3 months.*  
230 *Septicaemia.” (England)<sup>56</sup>*

231

232 In their studies of PWID with endocarditis, Bearnot and colleagues<sup>63,64</sup> noted that deprived of housing  
233 interfered participants’ with care, including being ineligible for outpatient parenteral antimicrobial  
234 therapy and having no fixed address for follow-up clinic contacts.

235

236 In six studies<sup>53,54,56,58,59,62</sup> authors analysed how criminalizing possession of drugs or injecting equipment  
237 (and associated police enforcement) increased risk for injecting-related infections. When lacking safer

238 indoor places to prepare and consume drugs, participants described engaging in riskier practices to  
239 avoid being seen by police. This included preparing and injecting drugs in unhygienic abandoned  
240 buildings,<sup>58</sup> and compromising injecting preparation practice when hurrying and not using a filter, not  
241 using sterile water, and/or inadvertently injecting subcutaneously.<sup>53,56,58</sup>

242  
243 *“I don't even use cotton [a filter]... boom and I usually get it done. Like that. So, if the cops raid*  
244 *and... several times the cops have pulled over, come right up to me and I've already injected it in*  
245 *my arm before they hit me.” (USA)<sup>53</sup>*

246  
247 In their ethnography, Bourgois and colleagues<sup>59</sup> observed “greater and more antagonistic police  
248 surveillance” of African American PWID than of white PWID in San Francisco (USA), leading to racist,  
249 differential seizure of sterile syringes (obtained from legal needle and syringe programs). They observed  
250 police evict homeless encampments and confiscate possessions, causing PWID to miss medical  
251 appointments.

252  
253 Three studies<sup>58,65,66</sup> included analyses of how supervised consumption sites create safer spaces to reduce  
254 infection risks caused by lack of housing and criminalization, by facilitating individualized education on  
255 safer injecting techniques<sup>65</sup> and access to wound/abscess care.<sup>65,66</sup>

### 256 257 *Health care policies and practices*

258 In 13 studies, authors analysed why PWID delay or avoid medical care for injecting-related infections  
259 (often until infections had progressed and spread). Contributing factors were prior experiences of  
260 stigmatizing or discriminatory care (in 12 studies<sup>53,54,60,61,64,67–73</sup>) and of untreated pain and withdrawal  
261 (in six studies<sup>53,61,63,64,71,72</sup>). In several studies, PWID described both:

262

263 *“I'm not trying to get drugs. I'm trying to get you to take your sharp scalpel, cut this fucking*  
264 *thing open, squeeze this shit out of me, and get me the fuck out of here. That's the pain relief*  
265 *that I want you to give me...I can do heroin; your little 5mg Percocet ain't doing nothing for me.*  
266 *But they automatically think when you come in, 'I got an abscess. I'm hurting', 'Oh, you're trying*  
267 *to get drugs', this and that... it does prevent a lot of people from going.” (USA)<sup>53</sup>*

268

269 Some negative experiences were driven by hospital policies. Harris<sup>61</sup> explains how a London hospital  
270 policy mandates that urine drug screens be obtained before methadone can be dispensed, even if the  
271 dose is confirmed by pharmacies or treatment programs. This caused delays or missed dosages of  
272 methadone, and resulting experiences of opioid withdrawal led PWID to stay away:

273

274 *“Mainly because how I have been treated at the hospitals, which is just like fucking dirt you'd*  
275 *find on your shoe... also being scared that I was going to be rough [sick] ...because if they didn't*  
276 *[give] me Methadone, like someone's said he [doctor] won't do it unless he would have to, and if*  
277 *you don't know your rights, but yeah, it was that that really scared me more than anything, was*  
278 *being sick [in withdrawal] in a hospital.” (England)<sup>61</sup>*

279

280 Four studies<sup>60,61,67,69</sup> included analyses of how delays in care due to negative experiences in health care  
281 settings had a disproportionate impact by race or gender. Assessing hospital care experiences in  
282 Vancouver (Canada), McNeil and colleagues<sup>67</sup> described, “Many participants of Aboriginal ancestry  
283 further expressed that institutionalized racism reinforced the view among hospital staff that they were  
284 ‘drug-seeking’”. Three studies included descriptions of how PWID who were mothers were discouraged  
285 from accessing care for injecting-related infections, including feelings of shame at disclosing substance

286 use as a mother,<sup>60</sup> and fear of child apprehension if their substance use was reported by health  
287 professionals.<sup>61,69</sup>

288

289 In four studies,<sup>63,67,70,74</sup> PWID described leaving hospital prematurely, before completing treatment for  
290 injecting-related infections. Explanations included leaving hospital in response to discrimination<sup>67,74</sup> and  
291 because restrictions on their movements in hospital triggered post-traumatic stress.<sup>63</sup> Two studies<sup>67,70</sup>  
292 highlighted participants being involuntarily discharged from hospital because of drug use, despite  
293 ongoing medical need. Jafari and colleagues<sup>74</sup> evaluated experiences with a care model intending to  
294 overcome these issues: clients at a residential, harm-reduction oriented program for people with severe  
295 injecting-related infections in Vancouver, Canada, described receiving less judgmental and stigmatizing  
296 care compared to their experience in mainstream hospitals.

297

298 Only one study specifically explored insufficient health insurance as a barrier to care.<sup>69</sup> In other studies,  
299 authors explained that insurance is a barrier to health care for some PWID but their study participants  
300 had access to public health insurance (universally in Canada<sup>67</sup>, and Medicaid in USA<sup>63,64</sup>).

301

### 302 *Harm reduction programs*

303 In four studies,<sup>52,55,56,71</sup> authors analysed consequences of PWID having insufficient or nonpreferred drug  
304 preparation and injecting equipment distributed from harm reduction programs. In their study of  
305 experiences of skin and soft-tissue infections in Glasgow (Scotland), Dunleavy and colleagues<sup>52</sup> report:  
306 “reasons for re-using [needles and syringes included having been] accidentally supplied with the wrong  
307 sized needles and preferring to re-use than use the wrong needle”. Three of these studies describe  
308 PWID lacking needed equipment and repurposing alcohol skin swabs distributed by harm reduction  
309 programs: to clean up blood after injecting,<sup>52,71</sup> to filter visible particulate matter out of puddle water

310 when lacking access to sterile water,<sup>56</sup> and burning swabs to obtain an adequate flame to heat the drug  
311 solution when lacking a sufficient lighter.<sup>52</sup> In two studies, Harris and colleagues explored how  
312 legal/regulatory and funding restrictions on harm reduction programs limited the distribution of sterile  
313 water<sup>56</sup> or single-use ascorbic acid packets.<sup>55</sup>

314  
315 In three studies, participants described structural barriers to needle and syringe programs that limited  
316 effectiveness. This included limited operating hours (e.g. closures on weekends<sup>52</sup>) and restricted  
317 eligibility.<sup>67,73</sup> McNeil and colleagues<sup>67</sup> assessed consequences of PWID being unable to access sterile  
318 equipment in hospital, leading to reuse of contaminated equipment:

319  
320 *“[Nurses] don’t give rigs [syringes] to us. ...I think that they should. If not, we’re reusing our rigs*  
321 *or we’re having to risk getting kicked out for stealing them or people’ll be sharing them. ...I know*  
322 *one girl was using her same rig for days to the point where it was tearing and she was suffering*  
323 *every time she’d do her fix. She just didn’t have it in her to go and try and steal clean rigs.”*  
324 (Canada)<sup>67</sup>

325  
326 Four further studies<sup>62,68,75,76</sup> focused on places without local needle and syringe programs (in USA and  
327 Mexico), where PWID were also unable to purchase syringes at pharmacies due to refusal from  
328 pharmacists:

329  
330 *“I think that many [pharmacists] think that by prohibiting the sale of syringes that they are going*  
331 *to stop the usage of drugs...but what they are doing is wrong, because of that we have a harder*  
332 *time finding syringes. We need to use drugs in order to feel well, since when we are in need of a*

333 *fix we feel desperate enough that we don't care and borrow one from a friend, since it's a*  
334 *desperate feeling..." (Mexico)<sup>76</sup>*

335  
336 Paquette and colleagues<sup>68</sup> explored how PWID would prefer having multiple access points for sterile  
337 injecting equipment, including from both pharmacies and needle and syringe programs: "...one  
338 participant indicated that using the [needle and syringe program] could out him as a PWID and expose  
339 him to stigma from others because [needle and syringe programs] exclusively serve PWID. If PWID could  
340 consistently access syringes at a pharmacy without fear of discrimination, some might prefer this option  
341 because it offers a higher level of anonymity than [needle and syringe programs]."<sup>68</sup>

342  
343 Two studies highlighted how suboptimal delivery of OAT after hospital discharge could increase risks for  
344 recurrent infections, including involuntary discharge from OAT because of ongoing use,<sup>63</sup> waiting  
345 lists,<sup>63,64</sup> and a lack of coordination.<sup>64</sup>

346  
347 *"So I had methadone maintenance while I was in the hospital and I did not really have anything*  
348 *lined up when I left [hospital], which, ultimately, could be one of the many reasons why I ended*  
349 *up re-infecting my valve and back in the hospital."* (USA)<sup>64</sup>

350  
351 *Mutual care*

352 Five studies<sup>52,53,60,62,71</sup> included descriptions of PWID caring for each other to promote health and reduce  
353 risks of infections. Within constraining risk environments, some of these protective strategies for  
354 bacterial infections precipitated other health risks.

355



356 Mutual care practices include providing or receiving education from fellow PWID,<sup>52</sup> sharing sterile  
357 needles or injecting equipment in settings of scarcity,<sup>62</sup> and offering or receiving assistance with  
358 injecting to reduce infection risks<sup>53,60</sup>;

359

360 *“I have my boyfriend. I only hit with him, always with him. I do not like to do it with strangers or*  
361 *people to whom I do not know so well. ... My boyfriend helps me, because when I do it, it swells*  
362 *up.” (USA)<sup>60</sup>*

363

364 Once infections developed, study participants described providing or receiving wound care and abscess  
365 treatment or antibiotics from peers in order to avoid negative experiences with the health care  
366 system.<sup>53,71</sup>

367

368 While navigating risk environments, protective strategies for bacterial infections could precipitate other  
369 health risks. For example, three studies<sup>55,60,77</sup> assessed particular risks that women PWID face when  
370 relying on assisted injecting in the context of gendered power dynamics. In their study, Epele<sup>60</sup> explored  
371 these trade-offs: “Abscesses and scars that are more frequent with muscle injection lead to further  
372 subordination within the hierarchies of their social networks, and deteriorate the women’s precarious  
373 strategies of income production. Although being injected by another increases the probability of HIV  
374 infection, it simultaneously prevents the visible physical damage that subjects these women to greater  
375 vulnerability.” Similarly, nonmedical abscess treatment or use of potentially inappropriate from  
376 nonmedical sources can lead to worsening infections, but PWID described employing these strategies to  
377 avoid negative experiences in health care settings.<sup>53,71</sup>

378

379 *Self-care*

380 Twelve studies<sup>52,53,56–58,60,63–65,68,71,76</sup> included analyses of participants’ practices to prevent and treat  
381 bacterial infections. These included practices to promote vein and skin care, including staying  
382 hydrated,<sup>71</sup> rotating injecting sites,<sup>60</sup> taking extra time to access veins,<sup>53,57,71</sup> asking for help to access  
383 veins,<sup>60,77</sup> and self-treating superficial abscesses (e.g., incision and drainage; nonmedical sources of  
384 antibiotics) before they progressed.<sup>53,68,71</sup>

385

386 *“Little things like drink a lot of liquids, make sure you sleep every night. Make sure you get*  
387 *enough sleep, drink liquids, eat regularly.” (USA)<sup>71</sup>*

388

389 In three of these studies, authors highlighted actions to mitigate the risks of poor-quality drugs or  
390 injecting equipment, including sharpening the tips of used needle tips to avoid vein damage (when  
391 unable to access new needles),<sup>76</sup> sourcing safer water by asking passers-by for bottled water,<sup>56</sup> and using  
392 ascorbic acid (which is safer than citric acid or lemon juice) when preparing heroin.<sup>55</sup>

393

394 In five studies, participants also described changing their drug use practices after experiencing an  
395 infection, to avoid another one. This included applying new learnings on safer injecting techniques,<sup>52,64,65</sup>  
396 switching from injecting to smoking,<sup>52</sup> getting wounds assessed by a nurse,<sup>52</sup> using the minimum  
397 required acidifier to dissolve drugs,<sup>55</sup> and seeking addiction treatment to reduce or abstain from  
398 injection use.<sup>63</sup>

399

400 Three studies included descriptions of self-care practices of PWID to avoid discrimination and structural  
401 stigma. This included injecting in central veins at hidden sites to avoid scars at more visible peripheral  
402 sites,<sup>52,60</sup> and using in unhygienic abandoned buildings to avoid being seen.<sup>58</sup>

403

404 Some of these protective self-care strategies employed within constraining risk environments also led to  
405 other potential health risks. For example, injecting in central veins in the groin to avoid discrimination  
406 from visible scars increases risks of thrombosis and arterial injury, and likely increase risks for bacterial  
407 infections (as the groin has a higher burden of bacterial colonisation). Considering unintended harms of  
408 inappropriate self-treatment of bacterial infections, Gilbert and colleagues<sup>71</sup> write: “There are certainly  
409 risks conferred by the self-care practices that PWID are forced to resort to. However, these risks are not  
410 taken lightly by PWID; they are weighed against the risk of inaction and worsening infections, which is  
411 well known in these communities.”

412

## 413 **DISCUSSION**

414 We reviewed qualitative studies on experiences of injection drug use-associated bacterial and fungal  
415 infections, and used thematic synthesis to identify social-structural factors influencing risk for these  
416 infections. These include poor quality of unregulated drugs, insufficient housing, policing practices,  
417 limited harm reduction services, and harmful health care practices. These are shaped by macro-  
418 environmental factors including structural stigma, criminalization, government austerity, and racism. We  
419 also identified ways in which PWID care for themselves and others to prevent and treat injecting-related  
420 infections, including by sharing sterile equipment and treating infections outside of medical settings.  
421 Within constraining risk environments, PWID face trade-offs and some of these protective strategies  
422 precipitated other health risks (e.g. in some circumstances of assisted-injecting). Enabling environment  
423 interventions that address these social-structural factors could further empower people who inject  
424 drugs to protect themselves and their community. While the importance of education on safer injecting  
425 technique came up in several studies,<sup>52,53,55,66,76</sup> our findings suggest that individual-level behavioural  
426 interventions alone are likely insufficient to reduce risk.

427

428 Several social-structural determinants of bacterial and fungal infections (as well as practices of mutual-  
429 and self-care<sup>35,78</sup>) that we identified are consistent with prior studies examining risk for HIV and HCV  
430 among PWID.<sup>27,29,42,79</sup> Insecure housing, hurrying injections to avoid police, insufficient harm reduction  
431 services, and laws restricting sterile injecting equipment are known to contribute to HCV<sup>79</sup> and HIV<sup>27</sup>  
432 risks. Stigmatizing and discriminatory health care experiences similarly discourage HCV and HIV  
433 treatment access and exacerbate health inequities.<sup>30,80</sup> Compared to the literature on HIV and HCV  
434 among PWID,<sup>81,82</sup> we identified relatively little published research considering intersectionality and risk  
435 for injecting-related bacterial or fungal infections.<sup>42</sup> A qualitative study by Hrycko and colleagues  
436 published after we conducted our search identified several social-structural factors contributing to risk  
437 for severe bacterial infections, including availability and use of drugs (e.g. fentanyl, stimulants)  
438 associated with a shorter duration of effect and more frequent injecting, and lack of access to sterile  
439 water.<sup>83</sup>

440  
441 A key motivation for our review was to identify potential opportunities to reduce risks for injecting-  
442 related bacterial and fungal infections. Many social-structural factors that we identified are modifiable,  
443 and some have already been resolved or ameliorated in some places. These include PWID organizing to  
444 access better quality, regulated drugs including via injectable OAT (with liquid formulations of  
445 diacetylmorphine, hydromorphone, or fentanyl), and through “safe supply” prescribing programs or  
446 compassion clubs.<sup>84–86</sup> Injectable OAT is associated with low risk for bacterial infections even when  
447 injected intramuscularly, since sterile, liquid formulations of drugs are provided in a hygienic and safe  
448 environment.<sup>87</sup> Social and supportive housing (including Housing First) can help PWID access and  
449 maintain housing; some models combine housing with injectable OAT, safe supply, and/or supervised  
450 consumption sites.<sup>88–90</sup> In some jurisdictions PWID and their allies have successfully advocated for  
451 decriminalization of drug/syringe possession and for laws enabling supervised consumption sites.<sup>91</sup>

452 Several initiatives have improved health care experiences for PWID with injecting-related infections,<sup>92,93</sup>  
453 including incorporating harm reduction and cultural safety principles,<sup>61,94</sup> specialized addiction medicine  
454 consultation services,<sup>95-97</sup> needle and syringe programs,<sup>98,99</sup> and supervised consumption sites<sup>100,101</sup> into  
455 hospital care. Policy changes are needed at many hospitals to facilitate these initiatives.<sup>102,103</sup>

456  
457 Our study has three key limitations. First, our review only included studies describing experiences of  
458 injecting-related infections and we did not include all studies investigating determinants of risky  
459 injecting practices (e.g. subcutaneous injecting; reuse of contaminated equipment) unless explicitly  
460 connected to infections. Second, we did not include gray literature that might have discussed further  
461 social-structural factors beyond those we identified in peer-reviewed papers. Third, some  
462 commentators<sup>48,104</sup> have argued that qualitative evidence syntheses decontextualize the nuanced  
463 findings of qualitative studies (conducted in different settings, with different methods) and try to  
464 consolidate knowledge that is not generalizable. We undertook this approach to understand how social  
465 and structural factors shape risks for injecting-related infections in ways that may be impossible to  
466 assess with quantitative research.<sup>38,105</sup>

467

## 468 **Conclusions**

469 Injecting-related bacterial and fungal infections are shaped by modifiable social-structural factors,  
470 including unregulated drug quality, criminalization, insufficient housing, limited harm reduction services,  
471 and harmful health care practices. Enabling environment interventions that address these factors could  
472 further empower people who inject drugs to protect themselves and their community.

473 **ACKNOWLEDGMENTS**

474 We thank Louise Gillis (Research Data Librarian at Dalhousie University) for helpful feedback and  
475 assistance with our search strategy. We thank Drs. Lindsay Wallace (Cambridge University), Ashish  
476 Thakrar (University of Pennsylvania), and Paul Christine (Boston Medical Center) for helpful comments  
477 on earlier manuscript drafts.

478  
479 We acknowledge that TDB, MB, EC, and IK live and work in Mi'kma'ki, the ancestral and unceded  
480 territory of the Mi'kmaq, and DW lives and works in unsundered and unceded territory and  
481 traditional lands of Wolastoqiyik. This territory is covered by the Treaties of Peace and Friendship which  
482 the Mi'kmaq and Wolastoqiyik Peoples first signed with the British Crown in 1725. The treaties did not  
483 deal with surrender of lands and resources but in fact recognized Mi'kmaq and Wolastoqiyik title and  
484 established the rules for what was to be an ongoing relationship between nations. We are Treaty  
485 people.

486

487 **FUNDING**

488 TDB is supported by the Dalhousie University Internal Medicine Research Foundation Fellowship, a  
489 Canadian Institutes of Health Research Fellowship (CIHR-FRN# 171259), and through the Research in  
490 Addiction Medicine Scholars Program (National Institutes of Health/ National Institute on Drug Abuse;  
491 R25DA033211). For part of this work, he was supported by the Killam Postgraduate Scholarship, Ross  
492 Stewart Smith Memorial Fellowship in Medical Research, and Clinician Investigator Programme  
493 Graduate Stipend (all from Dalhousie University Faculty of Medicine). MB, EC, and IK were supported in  
494 this work via the Ross Stewart Smith Memorial Fellowship in Medical Research (PI: TDB). DL was funded  
495 by a National Institute of Health Research Doctoral Research Fellowship (DRF-2018-11-ST2-016). MH

496 was funded by a National Institute of Health Research Career Development Fellowship (CDF-2016-09-  
497 014).

498

499 The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
500 Department of Health and Social Care. These funders had no role in the conduct or reporting of the  
501 research.

502

### 503 **DECLARATIONS OF COMPETING INTEREST**

504 MB reports personal fees from AbbVie, a pharmaceutical research and development company, and  
505 grants and personal fees from Gilead Sciences, a research-based biopharmaceutical company, outside of  
506 the submitted work. The other authors report no competing interests.

507

508 **REFERENCES**

- 509 1. Brothers TD, Lewer D, Bonn M, Webster D, Harris M. Social and structural determinants of  
510 injecting-related bacterial and fungal infections among people who inject drugs: protocol  
511 for a mixed studies systematic review. *BMJ Open*. 2021 Aug 9;11(8):e049924.  
512 <http://doi.org/10.1136/bmjopen-2021-049924>
- 513 2. Gomes T, Kitchen SA, Taylor L, Men S, Murray R, Bayoumi AM, et al. Trends in  
514 Hospitalizations for Serious Infections Among People With Opioid Use Disorder in Ontario,  
515 Canada. *J Addict Med*. 2021 Oct 28; Publish Ahead of Print.  
516 <https://doi.org/10.1097/adm.0000000000000928>
- 517 3. Serota DP, Bartholomew TS, Tookes HE. Evaluating Differences in Opioid and Stimulant  
518 Use-associated Infectious Disease Hospitalizations in Florida, 2016–2017. *Clin Infect Dis*.  
519 2021 Oct 1;73(7):e1649–57. <https://doi.org/10.1093/cid/ciaa1278>
- 520 4. Meisner JA, Anesi J, Chen X, Grande D. Changes in Infective Endocarditis Admissions in  
521 Pennsylvania During the Opioid Epidemic. *Clin Infect Dis*. 2020;71(7):1664–70.  
522 <https://doi.org/10.1093/cid/ciz1038>
- 523 5. Lewer D, Freer J, King E, Larney S, Degenhardt L, Tweed EJ, et al. Frequency of healthcare  
524 utilisation by adults who use illicit drugs: a systematic review and meta-analysis.  
525 *Addiction*. 2020 Jun;115(6):1011–23. <https://doi.org/10.1111/add.14892>
- 526 6. Kim JH, Fine DR, Li L, Kimmel SD, Ngo LH, Suzuki J, et al. Disparities in United States  
527 hospitalizations for serious infections in patients with and without opioid use disorder: A  
528 nationwide observational study. *PLoS Med*. 2020 Aug 7;17(8):e1003247.  
529 <https://doi.org/10.1371/journal.pmed.1003247>
- 530 7. Wright A, Otome O, Harvey C, Bowe S, Athan E. The Current Epidemiology of Injecting  
531 Drug Use-Associated Infective Endocarditis in Victoria, Australia in the Midst of Increasing  
532 Crystal Methamphetamine Use. *Heart Lung Circ*. 2018 Apr 1;27(4):484–8.  
533 <https://doi.org/10.1016/j.hlc.2017.03.166>
- 534 8. Mosseler K, Materniak S, Brothers TD, Webster D. Epidemiology, microbiology, and clinical  
535 outcomes among patients with intravenous drug use-associated infective endocarditis in  
536 New Brunswick. *Can J Cardiol Open*. 2020;2(5):379–85.  
537 <https://doi.org/10.1016/j.cjco.2020.05.002>
- 538 9. Lewer D, Harris M, Hope V. Opiate Injection–Associated Skin, Soft Tissue, and Vascular  
539 Infections, England, UK, 1997–2016. *Emerg Infect Dis*. 2019 Sep 23;23(8):1400–3.  
540 <https://doi.org/10.3201/eid2308.170439>
- 541 10. Wurcel AG, Anderson JE, Chui KKH, Skinner S, Knox TA, Snyderman DR, et al. Increasing  
542 Infectious Endocarditis Admissions Among Young People Who Inject Drugs. *Open Forum*  
543 *Infect Dis*. 2016 Jul 26;3(3):ofw157. <https://doi.org/10.1093/ofid/ofw157>



- 544 11. Barocas JA, Eftekhari Yazdi G, Savinkina A, Nolen S, Savitzky C, Samet JH, et al. Long-term  
545 Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States:  
546 A Modeling Study. *Clin Infect Dis*. 2021 Dec 6;73(11):ciaa1346.  
547 <https://doi.org/10.1093/cid/ciaa1346>
- 548 12. McCarthy NL, Baggs J, See I, Reddy SC, Jernigan JA, Gokhale RH, et al. Bacterial Infections  
549 Associated With Substance Use Disorders, Large Cohort of United States Hospitals, 2012–  
550 2017. *Clin Infect Dis*. 2020 Oct 23;71(7):e37–44. <https://doi.org/10.1093/cid/ciaa008>
- 551 13. Cooper HLF, Brady JE, Ciccarone D, Tempalski B, Gostnell K, Friedman SR. Nationwide  
552 Increase in the Number of Hospitalizations for Illicit Injection Drug Use-Related Infective  
553 Endocarditis. *Clin Infect Dis*. 2007 Nov 1;45(9):1200–3. <https://doi.org/10.1086/522176>
- 554 14. Ronan MV, Herzig SJ. Hospitalizations Related To Opioid Abuse/Dependence And  
555 Associated Serious Infections Increased Sharply, 2002–12. *Health Aff (Millwood)*. 2016 Jan  
556 5;35(5):832–7. <https://doi.org/10.1377/hlthaff.2015.1424>
- 557 15. Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of  
558 injecting-related injury and disease among people who inject drugs. *Drug Alcohol Depend*.  
559 2017 Feb 1;171:39–49. <https://doi.org/10.1016/j.drugalcdep.2016.11.029>
- 560 16. Gordon RJ, Lowy FD. Bacterial Infections in Drug Users. *N Engl J Med*. 2005 Nov  
561 3;353(18):1945–54. <https://doi.org/10.1056/NEJMra042823>
- 562 17. Dwyer R, Topp L, Maher L, Power R, Hellard M, Walsh N, et al. Prevalences and correlates  
563 of non-viral injecting-related injuries and diseases in a convenience sample of Australian  
564 injecting drug users. *Drug Alcohol Depend*. 2009 Feb 1;100(1):9–16.  
565 <https://doi.org/10.1016/j.drugalcdep.2008.08.016>
- 566 18. Hope VD, Hickman M, Parry JV, Ncube F. Factors associated with recent symptoms of an  
567 injection site infection or injury among people who inject drugs in three English cities. *Int J*  
568 *Drug Policy*. 2014 Mar 1;25(2):303–7. <https://doi.org/10.1016/j.drugpo.2013.11.012>
- 569 19. Phillips KT, Stein MD. Risk Practices Associated with Bacterial Infections among Injection  
570 Drug Users in Denver, Colorado. *Am J Drug Alcohol Abuse*. 2010 Mar 1;36(2):92–7.  
571 <https://doi.org/10.3109/00952991003592311>
- 572 20. Roux P, Donadille C, Magen C, Schatz E, Stranz R, Curano A, et al. Implementation and  
573 evaluation of an educational intervention for safer injection in people who inject drugs in  
574 Europe: a multi-country mixed-methods study. *Int J Drug Policy*. 2021 Jan 1;87:102992.  
575 <https://doi.org/10.1016/j.drugpo.2020.102992>
- 576 21. Stein MD, Phillips KT, Herman DS, Keosaian J, Stewart C, Anderson BJ, et al. Skin-cleaning  
577 among hospitalized people who inject drugs: a randomized controlled trial. *Addiction*.  
578 2021 May;116(5):122–1130. <https://doi.org/10.1111/add.15236>

- 579 22. Phillips KT, Stewart C, Anderson BJ, Liebschutz JM, Herman DS, Stein MD. A randomized  
580 controlled trial of a brief behavioral intervention to reduce skin and soft tissue infections  
581 among people who inject drugs. *Drug Alcohol Depend*. 2021 Feb 27;108646.  
582 <https://doi.org/10.1016/j.drugalcdep.2021.108646>
- 583 23. Harvey M. The Political Economy of Health: Revisiting Its Marxian Origins to Address 21st-  
584 Century Health Inequalities. *Am J Public Health*. 2021 Feb;111(2):293–300.  
585 <https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2020.305996>
- 586 24. Holman D, Lynch R, Reeves A. How do health behaviour interventions take account of  
587 social context? A literature trend and co-citation analysis. *Health (N Y)*. 2018 Jul  
588 1;22(4):389–410. <https://doi.org/10.1177/1363459317695630>
- 589 25. Link BG, Phelan J. Social Conditions As Fundamental Causes of Disease. *J Health Soc Behav*.  
590 1995;35:80. <https://doi.org/10.2307/2626958>
- 591 26. Krieger N. Theories for social epidemiology in the 21st century: an ecosocial perspective.  
592 *Int J Epidemiol*. 2001 Aug 1;30(4):668–77. <https://doi.org/10.1093/ije/30.4.668>
- 593 27. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk  
594 environment for injecting drug users: the past, present, and future. *Lancet Lond Engl*. 2010  
595 Jul 24;376(9737):268–84. [https://doi.org/10.1016/s0140-6736\(10\)60743-x](https://doi.org/10.1016/s0140-6736(10)60743-x)
- 596 28. Rhodes T, Simic M. Transition and the HIV risk environment. *BMJ*. 2005 Jul  
597 23;331(7510):220–3. <https://doi.org/10.1136/bmj.331.7510.220>
- 598 29. Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural  
599 production of HIV risk among injecting drug users. *Soc Sci Med*. 2005 Sep 1;61(5):1026–44.  
600 <https://doi.org/10.1016/j.socscimed.2004.12.024>
- 601 30. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs:  
602 a review mapping the role of social factors. *Harm Reduct J*. 2013 May 7;10(1):7.  
603 <https://doi.org/10.1186/1477-7517-10-7>
- 604 31. Dasgupta N, Beletsky L, Ciccarone D. Opioid Crisis: No Easy Fix to Its Social and Economic  
605 Determinants. *Am J Public Health*. 2017 Dec 21;108(2):182–6.  
606 <https://doi.org/10.2105/ajph.2017.304187>
- 607 32. McLean K. “There’s nothing here”: Deindustrialization as risk environment for overdose.  
608 *Int J Drug Policy*. 2016 Mar 1;29:19–26. <https://doi.org/10.1016/j.drugpo.2016.01.009>
- 609 33. Amemiya J, Mortenson E, Heyman GD, Walker CM. Thinking Structurally: A Cognitive  
610 Framework for Understanding How People Attribute Inequality to Structural Causes.  
611 *Perspect Psychol Sci*. 2022 Aug 18;17456916221093592.  
612 <https://doi.org/10.1177/17456916221093593>

- 613 34. McNeil R, Small W. 'Safer environment interventions': A qualitative synthesis of the  
614 experiences and perceptions of people who inject drugs. *Soc Sci Med*. 2014 Apr;106:151–  
615 8. <https://doi.org/10.1016/j.socscimed.2014.01.051>
- 616 35. Harris M, Rhodes T. Venous access and care: harnessing pragmatics in harm reduction for  
617 people who inject drugs. *Addiction*. 2012 Jun;107(6):1090–6.  
618 <https://doi.org/10.1111/j.1360-0443.2011.03749.x>
- 619 36. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA  
620 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar  
621 29;372:n71. <https://doi.org/10.1136/bmj.n71>
- 622 37. Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in reporting the  
623 synthesis of qualitative research: ENTREQ. *BMC Med Res Methodol*. 2012 Nov  
624 27;12(1):181. <https://doi.org/10.1186/1471-2288-12-181>
- 625 38. Pluye P, Hong QN. Combining the Power of Stories and the Power of Numbers: Mixed  
626 Methods Research and Mixed Studies Reviews. *Annu Rev Public Health*. 2014;35(1):29–45.  
627 <https://doi.org/10.1146/annurev-publhealth-032013-182440>
- 628 39. Pluye P, Hong QN, Bush PL, Vedel I. Opening-up the definition of systematic literature  
629 review: the plurality of worldviews, methodologies and methods for reviews and  
630 syntheses. *J Clin Epidemiol*. 2016 May 1;73:2–5.  
631 <https://doi.org/10.1016/j.jclinepi.2015.08.033>
- 632 40. Rhodes T. The 'risk environment': a framework for understanding and reducing drug-  
633 related harm. *Int J Drug Policy*. 2002 Jun 1;13(2):85–94. [https://doi.org/10.1016/S0955-3959\(02\)00007-5](https://doi.org/10.1016/S0955-3959(02)00007-5)
- 635 41. Rhodes T. Risk environments and drug harms: A social science for harm reduction  
636 approach. *Int J Drug Policy*. 2009 May 1;20(3):193–201.  
637 <https://doi.org/10.1016/j.drugpo.2008.10.003>
- 638 42. Collins AB, Boyd J, Cooper HLF, McNeil R. The intersectional risk environment of people  
639 who use drugs. *Soc Sci Med*. 2019 Aug 1;234:112384.  
640 <https://doi.org/10.1016/j.socscimed.2019.112384>
- 641 43. Rhodes T, Wagner K, Strathdee SA, Shannon K, Davidson P, Bourgois P. Structural Violence  
642 and Structural Vulnerability Within the Risk Environment: Theoretical and Methodological  
643 Perspectives for a Social Epidemiology of HIV Risk Among Injection Drug Users and Sex  
644 Workers. In: O'Campo P, Dunn JR, editors. *Rethinking Social Epidemiology: Towards a  
645 Science of Change*. Dordrecht: Springer Netherlands; 2012. p. 205–30.  
646 [https://doi.org/10.1007/978-94-007-2138-8\\_10](https://doi.org/10.1007/978-94-007-2138-8_10)
- 647 44. Robertson R, Broers B, Harris M. Injecting drug use, the skin and vasculature. *Addiction*.  
648 2021 Jul;116(7):add.15283. <https://doi.org/10.1111/add.15283>

- 649 45. Moola S, Munn Z, Sears K, Sfetcu R, Currie M, Lisy K, et al. Conducting systematic reviews  
650 of association (etiology): The Joanna Briggs Institute's approach. *JBI Evid Implement*. 2015  
651 Sep;13(3):163–9. <https://doi.org/10.1097/xeb.0000000000000064>
- 652 46. Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The Mixed  
653 Methods Appraisal Tool (MMAT) version 2018 for information professionals and  
654 researchers. *Educ Inf*. 2018 Jan 1;34(4):285–91.  
655 <https://content.iospress.com/articles/education-for-information/efi180221>
- 656 47. Hong QN, Pluye P. A Conceptual Framework for Critical Appraisal in Systematic Mixed  
657 Studies Reviews. *J Mix Methods Res*. 2019 Oct 1;13(4):446–60.  
658 <https://doi.org/10.1177/1558689818770058>
- 659 48. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in  
660 systematic reviews. *BMC Med Res Methodol*. 2008 Jul 10;8(1):45.  
661 <https://doi.org/10.1186/1471-2288-8-45>
- 662 49. Guise A, Horyniak D, Melo J, McNeil R, Werb D. The experience of initiating injection drug  
663 use and its social context: a qualitative systematic review and thematic synthesis.  
664 *Addiction*. 2017;112(12):2098–111. <https://doi.org/10.1111/add.13957>
- 665 50. Harris M, Guy D, Picchio CA, White TM, Rhodes T, Lazarus JV. Conceptualising hepatitis C  
666 stigma: A thematic synthesis of qualitative research. *Int J Drug Policy*. 2021 Oct  
667 1;96:103320. <https://doi.org/10.1016/j.drugpo.2021.103320>
- 668 51. Yoon GH, Levensgood TW, Davoust MJ, Ogden SN, Kral AH, Cahill SR, et al. Implementation  
669 and sustainability of safe consumption sites: a qualitative systematic review and thematic  
670 synthesis. *Harm Reduct J*. 2022 Jul 5;19(1):73. [https://doi.org/10.1186/s12954-022-00655-](https://doi.org/10.1186/s12954-022-00655-z)  
671 [z](https://doi.org/10.1186/s12954-022-00655-z)
- 672 52. Dunleavy K, Hope V, Roy K, Taylor A. The experiences of people who inject drugs of skin  
673 and soft tissue infections and harm reduction: A qualitative study. *Int J Drug Policy*.  
674 2019;65:65–72. <https://doi.org/10.1016/j.drugpo.2018.09.001>
- 675 53. Harris RE, Richardson J, Frasso R, Anderson ED. Experiences with skin and soft tissue  
676 infections among people who inject drugs in Philadelphia: A qualitative study. *Drug*  
677 *Alcohol Depend*. 2018 Jun 1;187:8–12. <https://doi.org/10.1016/j.drugalcdep.2018.01.029>
- 678 54. Phillips KT, Altman JK, Corsi KF, Stein MD. Development of a risk reduction intervention to  
679 reduce bacterial and viral infections for injection drug users. *Subst Use Misuse*. 2013  
680 Jan;48(1–2):54–64.
- 681 55. Harris M, Scott J, Wright T, Brathwaite R, Ciccarone D, Hope V. Injecting-related health  
682 harms and overuse of acidifiers among people who inject heroin and crack cocaine in  
683 London: a mixed-methods study. *Harm Reduct J*. 2019 Nov 13;16(1):60.  
684 <https://doi.org/10.1186/s12954-019-0330-6>

- 685 56. Harris M, Scott J, Hope V, Wright T, McGowan C, Ciccarone D. Navigating environmental  
686 constraints to injection preparation: the use of saliva and other alternatives to sterile  
687 water among unstably housed PWID in London. *Harm Reduct J.* 2020 Apr 10;17(1):24.  
688 <https://doi.org/10.1186/s12954-020-00369-0>
- 689 57. Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. The Textures of Heroin: User  
690 Perspectives on “Black Tar” and Powder Heroin in Two U.S. Cities. *J Psychoact Drugs.*  
691 2016;48(4):270–8. <https://doi.org/10.1080/02791072.2016.1207826>
- 692 58. Harris RE, Richardson J, Frasso R, Anderson ED. Perceptions about supervised injection  
693 facilities among people who inject drugs in Philadelphia. *Int J Drug Policy.* 2018;52:56–61.
- 694 59. Bourgois P, Martinez A, Kral A, Edlin BR, Schonberg J, Ciccarone D. Reinterpreting ethnic  
695 patterns among white and African American men who inject heroin: a social science of  
696 medicine approach. *PLoS Med.* 2006 Oct;3(10):e452.
- 697 60. Epele ME. Scars, harm and pain: About being injected among drug using Latina women. *J*  
698 *Ethn Subst Abuse.* 2002;1(1):47–69. [https://doi.org/10.1300/J233v01n01\\_04](https://doi.org/10.1300/J233v01n01_04)
- 699 61. Harris M. Normalised pain and severe health care delay among people who inject drugs in  
700 London: Adapting cultural safety principles to promote care. *Soc Sci Med.* 2020 Sep  
701 1;260:113183. <https://doi.org/10.1016/j.socscimed.2020.113183>
- 702 62. Pollini RA, Paquette CE, Slocum S, LeMire D. ‘It’s just basically a box full of disease’-  
703 navigating sterile syringe scarcity in a rural New England state. *Addict Abingdon Engl.* 2021  
704 Jan;116(1):107–15. <https://doi.org/10.1111/add.15113>
- 705 63. Bearnot B, Mitton JA. “You’re Always Jumping Through Hoops”: Journey Mapping the Care  
706 Experiences of Individuals With Opioid Use Disorder-associated Endocarditis. *J Addict*  
707 *Med.* 2020 Apr 7; Publish Ahead of Print. <https://doi.org/10.1097/adm.0000000000000648>
- 708 64. Bearnot B, Mitton JA, Hayden M, Park ER. Experiences of care among individuals with  
709 opioid use disorder-associated endocarditis and their healthcare providers: Results from a  
710 qualitative study. *J Subst Abuse Treat.* 2019 Jul 1;102:16–22.  
711 <https://doi.org/10.1016/j.jsat.2019.04.008>
- 712 65. Krüsi A, Small W, Wood E, Kerr T. An integrated supervised injecting program within a care  
713 facility for HIV-positive individuals: a qualitative evaluation. *AIDS Care.* 2009  
714 May;21(5):638–44. <https://doi.org/10.1080/09540120802385645>
- 715 66. Small W, Wood E, Lloyd-Smith E, Tyndall M, Kerr T. Accessing care for injection-related  
716 infections through a medically supervised injecting facility: A qualitative study. *Drug*  
717 *Alcohol Depend.* 2008 Nov 1;98(1):159–62.  
718 <https://doi.org/10.1016/j.drugalcdep.2008.05.014>

- 719 67. McNeil R, Small W, Wood E, Kerr T. Hospitals as a “risk environment”: An ethno-  
720 epidemiological study of voluntary and involuntary discharge from hospital against  
721 medical advice among people who inject drugs. *Soc Sci Med*. 2014 Mar;105:59–66.  
722 <https://doi.org/10.1016/j.socscimed.2014.01.010>
- 723 68. Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: Health services experiences  
724 among people who inject drugs. *Int J Drug Policy*. 2018 Jul;57:104–10.  
725 <https://doi.org/10.1016/j.drugpo.2018.04.004>
- 726 69. Colwill JP, Sherman MI, Siedlecki SL, Burchill CN, Siegmund LA. A grounded theory  
727 approach to the care experience of patients with intravenous drug use/abuse-related  
728 endocarditis. *Appl Nurs Res*. 2021;57:N.PAG-N.PAG.  
729 <https://doi.org/10.1016/j.apnr.2020.151390>
- 730 70. Bodkin K, Delahunty-Pike A, O’Shea T. Reducing stigma in healthcare and law  
731 enforcement: A novel approach to service provision for street level sex workers. *Int J*  
732 *Equity Health*. 2015;14(1). <https://doi.org/10.1186/s12939-015-0156-0>
- 733 71. Gilbert AR, Hellman JL, Wilkes MS, Rees VW, Summers PJ. Self-care habits among people  
734 who inject drugs with skin and soft tissue infections: a qualitative analysis. *Harm Reduct J*.  
735 2019 Dec 12;16(1):69. <https://doi.org/10.1186/s12954-019-0345-z>
- 736 72. Summers PJ, Hellman JL, MacLean MR, Rees VW, Wilkes MS. Negative experiences of pain  
737 and withdrawal create barriers to abscess care for people who inject heroin. A mixed  
738 methods analysis. *Drug Alcohol Depend*. 2018 Sep 1;190:200–8.  
739 <https://doi.org/10.1016/j.drugalcdep.2018.06.010>
- 740 73. Meyer JP, Culbert GJ, Azbel L, Bachireddy C, Kurmanalieva A, Rhodes T, et al. A qualitative  
741 study of diphenhydramine injection in Kyrgyz prisons and implications for harm reduction.  
742 *Harm Reduct J*. 2020;17(1):86. <https://doi.org/10.1186/s12954-020-00435-7>
- 743 74. Jafari S, Joe R, Elliot D, Nagji A, Hayden S, Marsh DC. A Community Care Model of  
744 Intravenous Antibiotic Therapy for Injection Drug Users with Deep Tissue Infection for  
745 “Reduce Leaving Against Medical Advice.” *Int J Ment Health Addict*. 2015;13:49–58.  
746 <https://doi.org/10.1007/s11469-014-9511-4>
- 747 75. Case P, Ramos R, Brouwer KC, Firestone-Cruz M, Pollini RA, Fraga MA, et al. At the borders,  
748 on the edge: use of injected methamphetamine in Tijuana and Ciudad Juarez, Mexico. *J*  
749 *Immigr Minor Health*. 2008 Feb;10(1):23–33. <https://doi.org/10.1007/s10903-007-9051-0>
- 750 76. Pollini RA, Lozada R, Gallardo M, Rosen P, Vera A, Macias A, et al. Barriers to pharmacy-  
751 based syringe purchase among injection drug users in Tijuana, Mexico: a mixed methods  
752 study. *AIDS Behav*. 2010 Jun;14(3):679–87. <https://doi.org/10.1007/s10461-010-9674-3>



- 753 77. Sheard L, Tompkins C. Contradictions and Misperceptions: An Exploration of Injecting  
754 Practice, Cleanliness, Risk, and Partnership in the Lives of Women Drug Users. *Qual Health*  
755 *Res.* 2008 Nov 1;18(11):1536–47. <https://doi.org/10.1177/1049732308325838>
- 756 78. Kolla G, Strike C. Practices of care among people who buy, use, and sell drugs in  
757 community settings. *Harm Reduct J.* 2020 May 7;17(1):27.  
758 <https://doi.org/10.1186/s12954-020-00372-5>
- 759 79. Rhodes T, Treloar C. The social production of hepatitis C risk among injecting drug users: a  
760 qualitative synthesis. *Addiction.* 2008 Oct;103(10):1593–603.  
761 <https://doi.org/10.1111/j.1360-0443.2008.02306.x>
- 762 80. Krüsi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access  
763 and adherence among injection drug users. *Int J Drug Policy.* 2010 Jan 1;21(1):4–9.  
764 <https://doi.org/10.1016/j.drugpo.2009.08.003>
- 765 81. Bluthenthal RN. Structural racism and violence as social determinants of health:  
766 Conceptual, methodological and intervention challenges. *Drug Alcohol Depend.* 2021  
767 May;222:108681. <https://doi.org/10.1016/j.drugalcdep.2021.108681>
- 768 82. Touesnard N, Brothers TD, Bonn M, Edelman EJ. Overdose deaths and HIV infections  
769 among people who use drugs: shared determinants and integrated responses. *Expert Rev*  
770 *Anti Infect Ther.* 2022 May 26;0(0):1–5. <https://doi.org/10.1080/14787210.2022.2081152>
- 771 83. Hrycko A, Mateu-Gelabert P, Ciervo C, Linn-Walton R, Eckhardt B. Severe bacterial  
772 infections in people who inject drugs: the role of injection-related tissue damage. *Harm*  
773 *Reduct J.* 2022 May 2;19(1):41. <https://doi.org/10.1186/s12954-022-00624-6>
- 774 84. Bonn M, Palayew A, Bartlett S, Brothers TD, Touesnard N, Tyndall M. Addressing the  
775 Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The  
776 Potential Roles for Decriminalization and Safe Supply. *J Stud Alcohol Drugs.* 2020 Sep  
777 1;81(5):556–60. <https://doi.org/10.15288/jsad.2020.81.556>
- 778 85. BCCSU. Heroin Compassion Clubs: A cooperative model to reduce opioid overdose deaths  
779 & disrupt organized crime’s role in fentanyl, money laundering & housing unaffordability  
780 [Internet]. Vancouver, B.C.: British Columbia Centre on Substance Use.;  
781 [https://www.bccsu.ca/wp-content/uploads/2019/02/Report-Heroin-Compassion-](https://www.bccsu.ca/wp-content/uploads/2019/02/Report-Heroin-Compassion-Clubs.pdf)  
782 [Clubs.pdf](https://www.bccsu.ca/wp-content/uploads/2019/02/Report-Heroin-Compassion-Clubs.pdf)
- 783 86. Canadian Association of People Who Use Drugs (CAPUD). Safe Supply Concept Document  
784 [Internet]. 2019 Feb. <https://doi.org/10.5281/zenodo.5637607>
- 785 87. Meyer M, Eichenberger R, Strasser J, Dürsteler KM, Vogel M. «One prick and then it’s  
786 done»: a mixed-methods exploratory study on intramuscular injection in heroin-assisted  
787 treatment. *Harm Reduct J.* 2021 Dec 18;18(1):134. [https://doi.org/10.1186/s12954-021-](https://doi.org/10.1186/s12954-021-00584-3)  
788 [00584-3](https://doi.org/10.1186/s12954-021-00584-3)

- 789 88. Harris MT, Seliga RK, Fairbairn N, Nolan S, Walley AY, Weinstein ZM, et al. Outcomes of  
790 Ottawa, Canada’s Managed Opioid Program (MOP) where supervised injectable  
791 hydromorphone was paired with assisted housing. *Int J Drug Policy*. 2021 Dec  
792 1;98:103400. <https://doi.org/10.1016/j.drugpo.2021.103400>
- 793 89. Brothers TD, Leaman M, Bonn M, John Fraser, Amy Gillis, Michael Gniewek, et al.  
794 Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19  
795 isolation hotel shelters for people experiencing homelessness. *Drug Alcohol Depend*. 2022  
796 Jun 1;235:109440. <https://doi.org/10.1016/j.drugalcdep.2022.109440>
- 797 90. Bardwell G, Collins AB, McNeil R, Boyd J. Housing and overdose: an opportunity for the  
798 scale-up of overdose prevention interventions? *Harm Reduct J*. 2017 Dec 6;14(1):77.  
799 <https://doi.org/10.1186/s12954-017-0203-9>
- 800 91. McNeil R, Small W, Lampkin H, Shannon K, Kerr T. “People Knew They Could Come Here to  
801 Get Help”: An Ethnographic Study of Assisted Injection Practices at a Peer-Run  
802 ‘Unsanctioned’ Supervised Drug Consumption Room in a Canadian Setting. *AIDS Behav*.  
803 2014 Mar 1;18(3):473–85. <https://doi.org/10.1007/s10461-013-0540-y>
- 804 92. Brothers TD, Fraser J, Webster D. Caring for people who inject drugs when they are  
805 admitted to hospital. *CMAJ Can Med Assoc J*. 2021 Mar 22;193(12):E423–4.  
806 <https://doi.org/10.1503/cmaj.202124>
- 807 93. CRISM. Guidance Document on the Management of Substance Use in Acute Care  
808 [Internet]. Alberta: Canadian Research Initiative on Substance Misuse (CRISM) - Prairie  
809 Node; 2020. [https://crismprairies.ca/management-of-substance-use-in-acute-care-  
810 settings-in-alberta-guidance-document/](https://crismprairies.ca/management-of-substance-use-in-acute-care-settings-in-alberta-guidance-document/)
- 811 94. McCall J, Pauly B. Sowing a Seed of Safety: Providing Culturally Safe Care in Acute Care  
812 Settings for People who use Drugs. *J Ment Health Addict Nurs*. 2019 May 31;3(1):e1–7.  
813 <https://doi.org/10.22374/jmhan.v3i1.33>
- 814 95. Englander H, Englander H. “We’ve Learned It’s a Medical Illness, Not a Moral Choice”:  
815 Qualitative Study of the Effects of a Multicomponent Addiction Intervention on Hospital  
816 Providers’ Attitudes and Experiences. *J Hosp Med*. 2018 Nov 1;13(11).  
817 <https://doi.org/10.12788/jhm.2993>
- 818 96. Brothers T, Fraser J, MacAdam E, Hickcox S, L Genge, T O’Donnell, et al. Implementation  
819 and evaluation of a novel, unofficial, trainee-organized hospital addiction medicine  
820 consultation service. *Subst Abuse*. 2021;42(4):433–7.  
821 <https://doi.org/10.1080/08897077.2020.1856291>
- 822 97. Hyshka E, Morris H, Anderson-Baron J, Nixon L, Dong K, Salvalaggio G. Patient perspectives  
823 on a harm reduction-oriented addiction medicine consultation team implemented in a



- 824 large acute care hospital. *Drug Alcohol Depend.* 2019 Nov 1;204:107523.  
825 <https://doi.org/10.1016/j.drugalcdep.2019.06.025>
- 826 98. Brooks HL, O'Brien DC, Salvalaggio G, Dong K, Hyshka E. Uptake into a bedside needle and  
827 syringe program for acute care inpatients who inject drugs. *Drug Alcohol Rev.*  
828 2019;38(4):423–7. <https://doi.org/10.1111/dar.12930>
- 829 99. Brothers TD, Mosseler K, Kirkland S, Melanson P, Barrett L, Webster D. Unequal access to  
830 opioid agonist treatment and sterile injecting equipment among hospitalized patients with  
831 injection drug use-associated infective endocarditis. *PLoS ONE.* 2022 Jan  
832 26;17(1):e0263156. <https://doi.org/10.1371/journal.pone.0263156>
- 833 100. Dong KA, Brouwer J, Johnston C, Hyshka E. Supervised consumption services for acute care  
834 hospital patients. *CMAJ.* 2020 May 4;192(18):E476–9.  
835 <https://doi.org/10.1503/cmaj.191365>
- 836 101. Dogherty E, Patterson C, Gagnon M, Harrison S, Chase J, Boerstler J, et al. Implementation  
837 of a nurse-led overdose prevention site in a hospital setting: lessons learned from St.  
838 Paul's Hospital, Vancouver, Canada. *Harm Reduct J.* 2022 Feb 5;19(1):13.  
839 <https://doi.org/10.1186/s12954-022-00596-7>
- 840 102. Lennox R, Martin L, Brimner C, O'Shea T. Hospital policy as a harm reduction intervention  
841 for people who use drugs. *Int J Drug Policy.* 2021 Nov 1;97:103324.  
842 <https://doi.org/10.1016/j.drugpo.2021.103324>
- 843 103. Harris M, Holland A, Lewer D, Brown M, Eastwood N, Sutton G, et al. Barriers to  
844 management of opioid withdrawal in hospitals in England: a document analysis of hospital  
845 policies on the management of substance dependence. *BMC Med.* 2022 Apr 14;20(1):151.  
846 <https://doi.org/10.1186/s12916-022-02351-y>
- 847 104. Dixon-Woods M, Bonas S, Booth A, Jones DR, Miller T, Sutton AJ, et al. How can systematic  
848 reviews incorporate qualitative research? A critical perspective. *Qual Res.* 2006 Feb  
849 1;6(1):27–44. <https://doi.org/10.1177/1468794106058867>
- 850 105. Bjerre-Nielsen A, Glavind KL. Ethnographic data in the age of big data: How to compare  
851 and combine. *Big Data Soc.* 2022 Jan 1;9(1):20539517211069892.  
852 <https://doi.org/10.1177/20539517211069893>
- 853

854 TABLES

Table 1. Summary of included studies.

Study	Country	Qualitative study design	Sample	Focus of interviews/analysis	Conceptual or explanatory model(s)	Summary of findings
Bearnot 2019 <sup>64</sup>	USA	Individual interviews  Grounded theory	11 PWID with opioid injection-associated endocarditis  55% women; median age 38 years; 55% with “unstable housing”	Experiences of endocarditis care	None specified	Poor health outcomes among PWID with opioid injection-associated endocarditis are caused by stigma, delays or discontinuity of care, social and medical comorbidities, perceptions of addiction as a chronic and relapsing disease, and prolonged hospitalizations..
Bearnot 2020 <sup>63</sup>	USA	Secondary analysis of interview data from Bearnot 2019 <sup>64</sup>  Journey mapping analysis  Grounded theory	Same as Bearnot 2019	Patterns of care for endocarditis	None specified	People with opioid injection-associated endocarditis left care before medically advised because of poor care experiences, including undertreatment of withdrawal and pain and discrimination from clinicians. Following hospitalization, participants commonly engaged in outpatient addiction treatment and follow-up endocarditis care. Leaving outpatient addiction treatment often preceded rehospitalizations with recurrent infections.
Bodkin 2015 <sup>70</sup>	Canada	Individual interviews  Qualitative descriptive analysis	14 PWID recruited from an outreach program for sex workers in London, Ontario	Access to health care among PWID who do sex work	None specified	Sex workers who inject drugs avoided primary care and emergency department treatment of injecting-related infections because of experiences of stigmatization and

			100% women; age range 23-49 years; housing status not reported			criminalization. Participants experienced involuntary discharge from hospital and received suboptimal oral antibiotics because of abstinence-requiring policies in hospital.
Bourgois 2006 <sup>59</sup>	USA	Mixed methods  Participant-observation ethnography (field notes, interviews, photographs)	Sample not specifically described, but includes African American and white men who inject heroin in San Francisco, California	How social-structural determinants interface with drug consumption practices and survival strategies among African American and white PWID	“...a social science theoretical understanding of the link between large-scale power relations and individual risky practices that shape the spread of blood-borne disease among injectors.”	Higher rates of abscesses among white PWID compared to African American PWID reflect socially produced differences in norms between racial/ethnic groups, including social acceptability of subcutaneous injecting among white PWID. Conversely, police are more likely to repeatedly search and confiscate sterile injecting equipment from African American PWID.
Case 2008 <sup>75</sup>	Mexico	Individual interviews  Thematic content analysis	43 PWID recruited through street-based outreach, shooting galleries, and drug treatment programs in Tijuana (n=20) and Ciudad Juárez (n=23)  42% women; median age 30; 30% lived or slept	Injection methamphetamine use in two Mexican border cities	Structural vulnerability	Greater availability of methamphetamine in Tijuana is associated with widespread use, compared to Ciudad Juárez. Injecting methamphetamine is perceived to be associated with increased risk of injecting-site abscesses, described more commonly in Tijuana.

			“on streets” in past six months			
Colwill 2021 <sup>69</sup>	USA	Individual interviews  Grounded theory	11 PWID undergoing surgical evaluation for injecting-related endocarditis  45% women; mean age 31; 9% “Homeless”	Experiences of endocarditis	“PWID with Endocarditis Cyclical Experiences (PEaCE) model”	PWID with endocarditis avoid health care because of stigmatizing and discriminatory experiences. The experience of endocarditis motivated some participants to enter addiction treatment and pursue abstinence.
Dunleavy 2019 <sup>52</sup>	Scotland	Individual interviews  Framework analysis	22 PWID who had experienced a skin and soft-tissue infection within past year, recruited from needle and syringe program (Glasgow; n=14) or drug treatment service (Edinburgh; n=8)  32% women; median 36 years; 59% experienced homelessness during the past six months	Experiences of skin and soft-tissue infections	Rhodes’ risk environment	Stigma associated with skin and soft-tissue infections motivated some participants to try to reduce risks, including use of sterile equipment and safer injecting techniques. No participants had learned about infections and associated risks from harm reduction programs. Social and environmental factors contributing to infection risk included insufficient access to sterile injecting equipment, caustic adulterants in the local drug supply, and a lack of hygienic spaces to prepare and consume drugs.
Epele 2002 <sup>60</sup>	USA	Individual interviews, observations, and	35 PWID recruited through syringe service	Risk conditions and care practices related to HIV	Political economy of health	Some women who inject drugs rely on injecting assistance from others to avoid intramuscular injection and

		<p>participation in everyday life settings</p> <p>Analysis approach not specified</p>	<p>program and snowball sampling</p> <p>71% women; mean age of women was 34; all “do not consider themselves as homeless”</p>	among Latino women	Biopower	<p>associated abscesses and scars, because these lead to loss of social status and negatively affect relationships and potential income generation through sex work. Participants recognized that assisted-injecting increases risks for HIV infection. Injection assistance is provided by friends, romantic or sexual partners, and paid “hit doctors”.</p>
Gilbert 2019 <sup>71</sup>	USA	<p>Secondary analysis of interview data from Summers 2018<sup>72</sup></p> <p>Thematic analysis</p>	<p>Same sample as qualitative sample in Summers 2018<sup>72</sup></p> <p>12 clients of a syringe services program in Boston (n=6) and Sacramento (n=6)</p> <p>25% women; median 46 years; housing status not reported</p>	Experience of skin and soft-tissue infections	<p>Health belief model (HBM) of health-seeking behaviors</p> <p>Conceptual Model of Medical Care Avoidance</p>	<p>PWID had good knowledge about skin infections and avoided formal health care due to traumatic experiences, discrimination, and unnecessarily painful procedures. Participants described multiple strategies for prevention and treatment of injecting-related infections including hydration, topical applications, non-prescribed antibiotics, and incision and drainage by non-medical providers.</p>
Harris RE 2018a <sup>53</sup>	USA	<p>Individual interviews</p> <p>Analysis approach not specified</p>	<p>19 clients of a syringe services program in Philadelphia</p> <p>53% women; median age 39 [27-59 years];</p>	Experiences of skin and soft-tissue infections	None specified	<p>PWID described good knowledge about risks of injecting-related skin infections, but were prevented from using hygienic techniques as they lacked of safe places to use drugs. Participants therefore injected abandoned buildings or outdoors, with inadequate lighting, or fear of assault</p>

			housing status not reported			or arrest, leading to drug contamination and intramuscular injection. Participants tended to avoid medical care for injecting-related infections due to prior negative healthcare experiences, including stigma and inadequate treatment of withdrawal and pain. Some participants described self-treatment of infections, including increased drug use for pain control and performing incision and drainage on themselves.
Harris RE 2018b <sup>58</sup>	USA	Individual interviews  Thematic analysis	Same sample as Harris RE 2018a <sup>53</sup> .  19 clients of a syringe services program in Philadelphia.  53% women; median 39 years; housing status not reported	Perceptions of safe injecting facilities	Rhodes' risk environment	PWID described commonly being forced to inject in public spaces, which led them to rush and inject intramuscularly or subcutaneously for fear of assault or arrest. Participants supported the idea of a supervised injection site to reduce these risks and inject more safely. Participants with stable housing preferred to inject at home and described that this reduced risks of injecting-related infections due to less fear of assault or arrest, adequate light and heat, running water, and space to store sterile injecting equipment.
Harris M 2019 <sup>55</sup>	England	Mixed methods  Individual interviews  Constructivist grounded theory	31 PWID recruited through drug treatment services, homeless hostels, and day centres	Use of acidifiers	Rhodes' risk environment	Excessive acidifier use in drug preparation for injection is common and contributes to venous damage and risk for bacterial infections. Some participants determined the amount of acidifier to use through expert practice (e.g., visual cue of solution

			<p>across London, UK</p> <p>29% women; mean age 43 years; housing status not reported</p>			<p>clarity) and others through external factors (e.g., using one whole packet of acid, even if that is excessive and causes pain and injury). Some participants decreased acidifier use over time, in response to new information or pain/injury. The authors infer a need to revisit design and distribution of acidifiers within harm reduction programs.</p>
Harris M 2020a <sup>61</sup>	England	<p>Individual interviews</p> <p>Constructivist grounded theory</p>	<p>36 PWID, recruited through specialist drug services, homeless hostels, and day centres across London, UK.</p> <p>12% women; mean 46 years; 64% unstably housed in past 12 months.</p>	Experiences of injecting-related injuries and infections	<p>Everyday violence</p> <p>Structural violence</p> <p>Cultural safety</p>	<p>Engagement with the medical system (including for injecting-related infections) is a “last resort”; often participants delayed as long as possible to the point that they were critically ill. Participants avoided or delayed accessing medical care for their own protection, including because of experiences of discrimination and undertreated withdrawal and pain; one participant specifically worried of stigma against mothers who use drugs and associated risks of child apprehension. Participants described leaving hospital prematurely and self-treating wounds instead.</p>
Harris M 2020b <sup>56</sup>	England	<p>Mixed methods</p> <p>Individual interviews</p> <p>Constructivist grounded theory</p>	<p>32 PWID, recruited through specialist drug services, homeless hostels, and day centres</p>	Water for preparing injecting solutions	Rhodes’ risk environment	<p>Environmental constraints to sourcing sterile water for injection preparation (and staying hydrated to promote vein health) include lack of housing, public washrooms, or sterile water from harm reduction programs. When injecting in public places, fear of arrest</p>

			<p>across London, UK.</p> <p>31% women; mean age 43 years; 94% had experienced homelessness</p>			<p>would lead people to rush their preparation and inject as fast as possible. As a result, participants described using more readily available but unsafe alternative water sources including puddle water, toilet cistern water, whisky, cola soda, and saliva to prepare injections, which were associated with bacterial infections. Participants described several strategies to promote health and safety despite these environmental constraints, including filtering water through alcohol swabs or asking passers-by for bottled water.</p>
Jafari 2015 <sup>74</sup>	Canada	<p>Mixed methods</p> <p>Individual interviews; direct observation and field notes</p> <p>Narrative analysis</p>	<p>8 PWID who were clients at a harm reduction-oriented medical respite program</p> <p>Gender, age, and current housing status not reported</p>	Experiences of care for injecting-related infections	None specified	<p>Participants described past experiences of leaving hospital before completion of their medical treatment because of judgmental and stigmatizing care. Clients with severe injecting-related infections who were being cared for at a harm reduction-oriented medical respite describe receiving less judgmental and stigmatizing care compared to their experience in acute care hospitals.</p>
Krüsi 2009 <sup>65</sup>	Canada	<p>Individual interviews</p> <p>Thematic analysis</p>	<p>22 PWID, recruited as clients at an HIV-focused residential and outpatient care facility in Vancouver</p>	Use of a supervised injection site integrated within a community-based HIV care facility	Rhodes' risk environment	<p>Participants accessing the supervised injection site found it a uniquely valuable setting to receive education on (and to implement) safer drug preparation and injecting techniques, which they attributed to reduced frequency of abscesses. When they did not have access to the supervised</p>



			32% women; mean 44 years; housing status not reported			injecting facility, participants described rushing their drug preparation and injection out of fear, including not using water to dissolve their heroin sufficiently.
Mars 2016 <sup>57</sup>	USA	Ethnography and individual interviews  Grounded theory	41 PWID recruited during ethnographic insertion in drug using community and with snowball sampling in Philadelphia (n=22) and San Francisco (n=19)  49% women; age unknown; homelessness "common".	Comparing perspectives of PWID in two different heroin markets.	Rhodes' risk environment	In San Francisco, where heroin was mostly in "tar" form, participants attributed abscesses to the characteristics of tar heroin including poor solubility. In Philadelphia, where more-soluble power heroin as well as cocaine was widely available, participants attributed abscesses to missing veins (i.e., injecting subcutaneously or intramuscularly) and when injecting cocaine. The authors attribute regional differences in abscess risk to geopolitical forces that have segmented the U.S. heroin market.
McNeil 2014 <sup>67</sup>	Canada	Individual interviews  Thematic analysis	30 PWID who had experienced hospital discharge against medical advice within the prior two years, recruited from within a prospective cohort study in Vancouver  43% women; mean 45 years;	Hospital care experiences	Rhodes' risk environment  Social violence	Participants left hospital prematurely (before the completion of their recommended treatment) because of inadequate pain and withdrawal management, and because of discriminatory, stigmatizing, and racist care experiences. These were influenced by hospital policies, written and unwritten.

			27% staying in emergency shelters or unhoused			
Meyer 2020 <sup>73</sup>	Kyrgyzstan	Individual interviews Content analysis	11 PWID who were incarcerated and injected diphenhydramine  10% women; average age not reported; all currently incarcerated	Diphenhydramine injecting in Kyrgyz prisons	Rhodes' risk environment	Participants attributed severe skin infections to injecting diphenhydramine while incarcerated, particularly in comparison to injecting heroin. Infectious risks associated with diphenhydramine were influenced by the denial of access to the prison's needle and syringe program to people taking methadone (which was common among people injecting diphenhydramine) and stigmatization and punishment of diphenhydramine users in the prison (which led people to delay seeking care for skin infections).
Paquette 2018 <sup>68</sup>	USA	Individual interviews "Mixed inductive and deductive approach"	46 PWID who attended syringe service programs or health services in Fresno, California (n=22) or community services agencies or street-based recruitment in Kern, California (n=24)  37% women; mean 39 years;	Stigmatizing health care experiences	Rhodes' risk environment	Participants described delaying or avoiding medical care ("until it was absolutely necessary") for injecting-related infections because of previous stigmatizing experiences. Instead, some people treat their own infections. Participants in rural areas also described feeling as if they could not attend their local harm reduction program for sterile injecting equipment as this would "out" them as a drug user to the small community.

			housing status not reported			
Phillips 2013 <sup>54</sup>	USA	Mixed methods  Focus group interviews  Qualitative analysis approach not specified	32 PWID recruited through street outreach in Denver, Colorado  50% women; mean age 50 years; housing status not reported	Perspectives on injecting-related bacterial infections, to inform development of a behaviour change intervention	Information-Motivation-Behavioral Skills model	Most participants had experienced injecting-related bacterial infections. PWID attributed increased risk of infections to poor quality (or adulterated or contaminated) unregulated drugs, including tar heroin (compared to powder heroin or pharmaceutical opioid tablets); to injecting intramuscularly or subcutaneously; to reusing needles; and to not cleaning skin. Barriers to practicing safer drug preparation and injecting included lack of access to sterile equipment (influenced by a “paraphernalia law” that prohibited carrying a hypodermic needle without “proof of medical need”).  Participants described delaying or avoiding medical care for infections due to negative health care experiences.
Pollini 2010 <sup>76</sup>	Mexico	Mixed methods  Focus groups  Grounded theory	47 PWID invited from among participants in a cohort study that used respondent-driven sampling  14% women; age not reported;	Barriers to sterile syringe access, including purchase from pharmacies	Rhodes’ risk environment	Participants described many challenges in accessing sterile needles and syringes via purchasing at local pharmacies, including discrimination from pharmacists and pharmacists disclosing fear of “trouble with police” (despite syringe sales being legal). This led to syringe reuse being common practice. Participants did not spontaneously attribute risks for

			housing status not reported			abscesses to needle and syringe reuse, until asked by a focus group facilitator.
Pollini 2021 <sup>62</sup>	USA	Individual interviews  Thematic analysis	20 PWID recruited through provider referral, street-based recruitment and snowball sampling  45% women; median age 26; housing status not reported	Scarcity of sterile needles and syringes in a rural environment	Rhodes' risk environment	Scarcity of sterile needle and syringes led PWID to share and re-use syringes. Factors limiting sterile syringe access included pharmacies refusing to sell them or requiring an ID, and a state "drug paraphernalia" law that criminalizes possession of syringes. Participants would travel out-of-state to pharmacies that would sell syringes, but police were aware of this and would stop and search cars with out-of-state license plates after visiting a pharmacy. One participant obtained sterile syringes from a family member with diabetes and distributed them to people in her community who inject drugs.
Sheard 2008 <sup>77</sup>	England	Individual interviews  Grounded theory	45 women who inject drugs recruited among clients of needle and syringe programs and addiction treatment programs in semirural North Nottinghamshire and urban Leeds, and through snowball sampling of	Assistance with injecting among women.	None specified	All participants (100% women) were injected by others, sometimes by a male partner who exerted power and control. Some participants shared needles and injecting equipment with partners as an intimate practice. Participants attributed injecting-related bacterial infections to unintentional subcutaneous injecting when self-injecting, caused by inexperience and a lack of knowledge about how to inject safely. Self-injecting was a positive experience for some women as it promoted independence; for others, it caused

			<p>participant contacts.</p> <p>100% women; age range 16 – 46 years.</p>			<p>harm visible scars which worsened social marginalization. Most participants accessed a local needle exchange and had ample supply of sterile drug preparation and injecting equipment. Cleanliness and hygiene were commonly raised as important reasons to avoid reusing or sharing of equipment.</p>
Small 2008 <sup>66</sup>	Canada	<p>Individual interviews</p> <p>Thematic analysis</p>	<p>50 PWID who use supervised injection sites in Vancouver.</p> <p>42% women; median age 38; housing status not reported</p>	<p>Impact of the supervised consumption site on access to care for injecting-related bacterial infections.</p>	<p>None specified, but motivated by exploration of “social and structural barriers to care commonly experienced by [injection drug users]”</p>	<p>Participants described delaying or avoiding medical care because of previous negative experiences. By providing nonjudgmental care within a setting where drug use is accommodated, contact with nurses at a supervised injection site facilitated access to care for injecting-related infections.</p>
Summers 2018 <sup>72</sup>	USA	<p>Mixed methods</p> <p>Individual interviews</p> <p>Thomas’ general inductive approach</p>	<p>12 PWID recruited from needle and syringe programs in Boston, Massachusetts and Sacramento, California</p>	<p>Prevention and treatment of skin infections</p>	<p>Rhodes’ risk environment</p> <p>Health Belief Model (HBM) of health-seeking behaviours</p> <p>Conceptual Model of Medical Care Avoidance</p>	<p>Participants described delaying, avoiding, or prematurely leaving medical care for injecting-related skin and soft-tissue infections because of experiences of unaddressed pain and withdrawal symptoms, stigma.</p>

855

856 **FIGURE LEGENDS**

857 **Figure 1. Illustrative schematic of pathway model to conceptualize how the risk environment shapes**  
858 **risk for injecting-related bacterial and fungal infections at different moments.** Macro-environmental,  
859 micro-environmental, and individual-level factors interplay to influence risk at each moment.

860


861 **Figure 2. PRISMA flow diagram of included studies in systematic review and thematic synthesis of**  
862 **social and structural determinants of injection drug use-associated bacterial and fungal infections.**

863

864 **Figure 3. Schematic summary of analytic and descriptive themes on social and structural determinants**  
865 **of injection drug use-associated bacterial and fungal infections.**

866


867



868

869 **Figure 1. Illustrative schematic of pathway model to conceptualize how the risk environment shapes risk for injecting-related bacterial and**  
870 **fungal infections at different moments.** Macro-environmental, micro-environmental, and individual-level factors interplay to influence risk at  
871 each moment.  
872

873




874  
875  
876

**Figure 2. PRISMA flow diagram of included studies in systematic review and thematic synthesis of social and structural determinants of injection drug use-associated bacterial and fungal infections.**



877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903



**Figure 3. Schematic summary of analytic and descriptive themes on social and structural determinants of injection drug use-associated bacterial and fungal infections.**